FORM OF INDEMNITY AGREEMENTIndemnity Agreement • June 9th, 2021 • Innovatus Life Sciences Acquisition Corp. • Blank checks • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of , 2021, by and between Innovatus Life Sciences Acquisition Corp., a Delaware corporation (the “Company”), and (“Indemnitee”).
17,500,000 Shares of Class A Common Stock Innovatus Life Sciences Acquisition Corp. UNDERWRITING AGREEMENTUnderwriting Agreement • June 9th, 2021 • Innovatus Life Sciences Acquisition Corp. • Blank checks • New York
The Company has entered into an Investment Management Trust Agreement, dated as of the date hereof, with Continental Stock Transfer & Trust Company (“CST”), as trustee, in substantially the form filed as Exhibit 10.2 to the Registration Statement (the “Trust Agreement”), pursuant to which certain of the proceeds from the sale of the Private Placement Shares (as defined below) and the proceeds of the Offering will be deposited and held in a trust account (the “Trust Account”) for the benefit of the Company, the Underwriters and the holders of the Underwritten Securities and the Option Securities, if and when issued.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 9th, 2021 • Innovatus Life Sciences Acquisition Corp. • Blank checks • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [ ], 2021, is made and entered into by and among Innovatus Life Sciences Acquisition Corp., a Delaware corporation (the “Company”), Innovatus Life Sciences Acquisition Sponsor, LLC, a Delaware limited liability company (the “Sponsor”) and the undersigned parties listed on the signature page hereto under “Holders” (each such party, together with the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.02 of this Agreement, a “Holder” and collectively the “Holders”).
Innovatus Life Sciences Acquisition Corp. 777 Third Avenue, 25th Floor New York, NY 10017Innovatus Life Sciences Acquisition Corp. • June 9th, 2021 • Blank checks • Delaware
Innovatus Life Sciences Acquisition Corp., a Delaware corporation (the “Company”, “we” or “us”), is pleased to accept the offer made by Innovatus Life Sciences Acquisition Sponsor, LLC, a Delaware limited liability company (“Subscriber” or “you”), to purchase 585,000 shares (or 637,500 shares if the over-allotment option in connection with the IPO (as defined below) is exercised in full) (the “Shares”) of Class A common stock of the Company, $0.0001 par value per share (“Class A Common Stock”), at a price of $10.00 per share concurrently with the Company’s initial public offering (“IPO”). The terms of the sale by the Company of the Shares to Subscriber, and the Company and Subscriber’s agreements regarding the Shares, are as follows:
